细辛脑和沐舒坦在小儿喘息性疾病中的治疗效果比较

Comparison of therapeutic effect between asarone and ambroxol in pediatric asthmatic disease

目的探讨细辛脑和沐舒坦在小儿喘息性疾病治疗中的效果。方法102例小儿喘息性疾病患者随机分为细辛脑组和沐舒坦组，各51例。2组患者均给予常规补液、止咳、化痰、抗感染治疗，细辛脑组，给予细辛脑0.5 mg/kg, 1次/d, 静脉滴注，连用5～7 d; 沐舒坦组，给予沐舒坦0.5～1 mg/kg，喘定10 g/kg, 1次/d, 静脉滴注，连用5～7 d。结果细辛脑组发热、精神症状、咳嗽、喘息、肺部罗音、气急、紫绀的平均持续天数明显低于沐舒坦组；细辛脑组5 d治愈率为74.5%, 明显高于沐舒坦组的5 d治愈率（54.9%）; 细辛脑组治疗5 d的总有效率为98.0%, 明显高于沐舒坦组的5 d总有效率。结论细辛脑治疗小儿喘息性疾病比沐舒坦见效快、疗效高，但严重过敏体质小儿应慎用。

Objective To explore the efficacy differences between asarone and ambroxol in pediatric asthmatic disease. Methods A total of 102 patients with infantile asthmatic disease were randomly divided into asarone group （ n = 51 ） and ambroxol group （ n = 51 ）. Two groups received routine treatment of rehydration, cough relief, phlegm, and inflammation. Asarone group received asarone 0.5 mg/kg every time, once a day, intravenous infusion for 5 - 7 days. While ambroxol group received additional ambroxol 0.5 - 1 mg/kg a time, diprophylline 10 g/kg, 1/d, IV, lasing 5 -7 days. Results Compared with the asarone group, the average duration of fever, psychical symptoms, cough, asthma, pulmonary crackles, shortness of breath and cyanosis were lower in am- broxol group. The cure rate in asarone group at 5 d was 74.5 %, which was significantly higher than that in ambroxol group （54.9%）. The total therapeutic efficiency in asarone group at 5 d was 98 %, which was considerably higher than that in ambroxol group. Conclusion Asarone has quicker, better and higher efficacy in treating pediatric asthma than ambroxol. But it should be very cautious to use this on severe allergic children.